stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Shares outstanding
LivaNova PLC's shares outstanding at the end of fiscal 2025 was $54.5M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $57.4M. Over the past ten years it has ranged from $26.6M (fiscal 2015) to $54.6M (fiscal 2024); the current reading is higher than 91% of that period. LivaNova PLC ranks 53rd of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $54.5M | (0.05%) |
| FY2024 | $54.6M | 0.67% |
| FY2023 | $54.2M | 1.38% |
| FY2022 | $53.5M | 5.61% |
| FY2021 | $50.6M | 4.20% |
| FY2020 | $48.6M | 0.50% |
| FY2019 | $48.3M | (0.31%) |
| FY2018 | $48.5M | (0.01%) |
| FY2017 | $48.5M | (1.05%) |
| FY2016 | $49.0M | 84.08% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $57.4M | 1.95% |
| Jun 2026 | $56.3M | 0.58% |
| Mar 2026 | $55.9M | 2.56% |
| Dec 2025 | $54.5M | (1.10%) |
| 45 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| NEOG Neogen Corporation compare | $218.1M |
| BRKR Bruker Corporation compare | $152.5M |
| TXG 10x Genomics compare | $130.0M |
| AXGN AxoGen, Inc. compare | $61.5M |
| LIVN LivaNova PLC | $57.4M |
| HAE Haemonetics Corporation compare | $46.5M |
| ITGR Integer Holdings Corporation compare | $34.6M |
| IRTC iRhythm Holdings, Inc. compare | $33.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement